Table 1. Baseline characteristics.
Baseline characteristics (Total N = 211) | Frequency (pts/total applicable) | P (%) |
Age | ||
<70 Years | 111/205 | 54.1 |
>70 Years | 94/205 | 45.9 |
Gender | ||
Male | 172/211 | 81.5 |
Female | 39/211 | 18.5 |
Aetiology | ||
HBV-related | 35/211 | 16.5 |
HCV-related | 110/211 | 52.1 |
Alcohol-related cirrosi | 20/211 | 9.4 |
Other | 46/211 | 21.8 |
Grading | ||
G1 | 28/98 | 28.6 |
G2 | 30/98 | 30.6 |
G3 | 40/98 | 40.8 |
Locoregional Treatment | ||
No | 149/211 | 70.6 |
Yes | 62/211 | 29.4 |
Type of locoregional Treatment | ||
Surgery | 50/149 | 33.5 |
Interventional Radiology | 89/149 | 66.5 |
Type of interventional Radiology | ||
RFA | 23/89 | 25.8 |
TACE | 57/89 | 64.0 |
PEI | 9/89 | 10.1 |
CHILD Score | ||
A | 133/191 | 69.8 |
B | 42/191 | 22.0 |
C | 16/191 | 8.4 |
Visceral Metastasis | ||
Yes | 151/211 | 71.6 |
No | 60/211 | 28.4 |
AFP (cut-off value of 200 ng/mL at diagnosis) | ||
<200 ng/ml | 97/149 | 65.1 |
>200 ng/ml | 52/149 | 34.9 |
AFP (median value at diagnosis) | ||
<43 ng\ml | 75/149 | 50.4 |
>43 ng/ml | 74/149 | 49.6 |
Sorafenib Treatment | ||
Yes | 132/211 | 62.6 |
No | 79/211 | 37.4 |
Abbreviations: n, number; pts, patients; HBV, Hepatitis B virus; HCV, Hepatitis C virus.